Skip to content

Double Blind Placebo Controlled Study on the Effect of Extracorporal Shock Wave Therapy on Erectile Dysfunction in PDE5i Responders

The Effect of Low Intensity Shock Wave Therapy on Erectile Dysfunction in Patients Responding to PDE5i's

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01274923
Acronym
LI-ESWT
Enrollment
20
Registered
2011-01-12
Start date
2010-08-31
Completion date
2012-10-31
Last updated
2011-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Keywords

Erectile dysfunction, Low Intensity Shock Wave

Brief summary

This study aims to evaluate the effect of shockwave therapy on erectile dysfunction on patients responding to PDE5i therapy in a sham controlled randomized double blind manner.

Detailed description

This study aims to evaluate the effect of a 12-session low intensity shockwave therapy protocol for patients with erectile dysfunction. On screening patients will undergo evaluation by thorough medical history and by questionnaires for evaluation of sexual function. A one-month active treatment with PDE5i will be provided followed by re-evaluation using the same questionnaires. Then another one-month period without PDE5i medication (washout period ) will be done and finally on the following visit evaluation will include the same questionnaires and if fit for inclusion- additional objective evaluation of endothelial function using the Flow mediated dilatation technique and penile blood flow measurement by doppler ultrasound of the Penis will be performed. At the end of this screening pahse the first shock wave session will be performed. Altogether 12 treatment sessions will be performed - 6 treatments twice a week followed by a 3 week no-treatment interval and again 6 treatments twice a week. Follow-up which will include the same evaluation as in the first treatment visit will be performed one month after end of treatment

Interventions

shock wave treatment

Sponsors

Medispec
CollaboratorINDUSTRY
Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* ED of more than 6 months * Rigidity score ≥ 3 under PDE5i therapy * SHIM ≤21 under PDE5i therapy * Non- hormonal, neurological or psychological pathology * Stable heterosexual relationship for more than 3 months

Exclusion criteria

* Prior prostatectomy surgery * Any unstable medical, psychiatric, spinal cord injury and penile anatomical abnormalities * Clinically significant chronic hematological disease * Anti-androgens, oral or injectable androgens * Radiotherapy in pelvic region

Design outcomes

Primary

MeasureTime frameDescription
International Index of Erectile function- Erectile Function DomainAt screening and 17 weeks later at last visitAn increase in score of 5points and above will be considered success.

Secondary

MeasureTime frameDescription
Rigidity scaleAt screening and 17 weeks later at last visitA change from 1,2 to a result of 3 or 4 of the rigidity scale points will be considered success
Flow Mediated Dilatation TechniqueAt screening and 17 weeks later at last visitA specialized sphygmomanometer cuff located at the penile base, is inflated to 50 mm Hg for 5min to induce a venous filling. A mercury strain gauge is placed at least 1-2 cm above the penile cuff. Baseline penile blood flow is obtained. Postischemic penile blood flow is then recorded immediately after the deflation, until a return to baseline flow is observed. An increase in blood flow above 30% will be considered success.

Countries

Israel

Contacts

Primary ContactIlan Gruenwald, MD
i_gruenwald@rambam.health.gov.il00972544474341
Backup ContactYoram Gruenwald, Prof
yvardi@rambam.health.gov.il0097248542819

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026